Patents by Inventor Marco Cavallari

Marco Cavallari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carbohydrate-glycolipid conjugate vaccines
    Patent number: 10588962
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 17, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari
  • BRANCHED PROXIMITY HYBRIDIZATION ASSAY
    Publication number: 20180171382
    Abstract: The invention relates to a method for detecting the proximity of at least two biomolecules using branched DNA technology. The assay is called branched proximity hybridization assay.
    Type: Application
    Filed: June 27, 2016
    Publication date: June 21, 2018
    Inventors: Marco Cavallari, Jianying Yang, Michael Reth
  • CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES
    Publication number: 20150238597
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Application
    Filed: March 19, 2013
    Publication date: August 27, 2015
    Applicants: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari
  • Dispersion managed fiber optic cable and system
    Patent number: 6526208
    Abstract: A hybrid optical fiber comprises a first fiber section comprising a fiber or a concatenation of fibers having first dispersion characteristics at a predetermined operating wavelength and a second fiber section coupled to the first fiber section to form the hybrid fiber. The first fiber dispersion characteristics are selected to maintain the signal dispersion within desired limits, whereas the second fiber is optimised for low loss. Dispersion compensation is provided in the first section of the fiber span where the signal intensity is highest, and therefore the region of the fiber span where these non-linearities have greatest effect. In the second section of the fiber span, the non-linear effects can be ignored, so it is optimised for low loss rather than for dispersion compensation.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: February 25, 2003
    Assignee: Nortel Networks Limited
    Inventors: Jonathan King, Richard Epworth, Marco Cavallari, Alan Robinson, Benoit Charbonnier